文献速递神经肿瘤

阿贝西司他减弱替莫唑胺耐药胶质瘤干细胞

Abexinostat attenuates temozolomide-resistant glioma stem cells.
PubMed 文献 · Neuro Oncol · 2026-08-19

该研究通过患者来源肿瘤培养物和异种移植模型,探讨组蛋白去乙酰化酶抑制剂阿贝西司他对胶质母细胞瘤分化细胞和胶质瘤干细胞的作用。结果显示阿贝西司他可降低DNA修复机器和干细胞标志物、减少染色质可及性,并在体外和体内抑制肿瘤生长及间充质胶质瘤干细胞。

要点

  • 阿贝西司他降低DNA修复蛋白RAD51、CHK1、Ku70和MGMT并诱导凋亡。
  • 阿贝西司他减少干细胞自我更新及间充质干细胞标志物CD44和ALDH1A3。
  • 阿贝西司他在胶质母细胞瘤患者来源模型体内外均抑制肿瘤生长和干细胞特征。

核心结论

  • 阿贝西司他通过降低染色质可及性减少DNA修复机器和胶质瘤干细胞标志物,在体外和体内抑制肿瘤生长及间充质胶质瘤干细胞。

研究设计与样本

  • 研究使用患者来源肿瘤培养物体外测试阿贝西司他,并以ATAC-seq分析染色质可及性。
  • 采用单球体和碱性磷酸酶染色实验检测干细胞自我更新,以醛脱氢酶活性区分间充质胶质瘤干细胞。
  • 在表达CK9751的患者来源培养物和间充质患者来源异种移植模型中评估阿贝西司他与替莫唑胺的疗效。

主要发现

  • 在患者来源培养物CK9495和CK9751中,阿贝西司他降低DNA修复机器(RAD51、CHK1、Ku70和MGMT)并诱导凋亡。
  • 针对DNA修复和干性启动子的聚焦ATAC-seq分析显示阿贝西司他降低染色质可及性。
  • 阿贝西司他在体外胶质母细胞瘤模型中减少干细胞自我更新并降低间充质干细胞特征(CD44、ALDH1A3表达和ALDH1活性)。
  • 阿贝西司他在CK9751患者来源培养物和间充质患者来源异种移植模型中减少肿瘤生长和干性标志物。

临床怎么用

  • 阿贝西司他具有靶向胶质瘤干细胞和DNA修复机器的潜力,可能用于预防干细胞介导的治疗抵抗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most common adult primary brain malignancy. Recent studies demonstrate that temozolomide (TMZ) facilitates the persistence of quiescent glioma stem cells (GSCs), which are responsible for GBM recurrence. An ideal therapy should eradicate both proliferating cells and GSCs. Abexinostat (Abx), a histone deacetylase inhibitor, was identified through connectivity mapping to target the specific GBM signature. Here, we demonstrate the anti-proliferative effect of Abx on both differentiated cells and GSCs. METHODS: Using patient-derived tumor cultures (PDCs) to test Abx in vitro, ATAC-seq identified chromatin accessibility. Single-spheroid and alkaline phosphatase staining assays were used to test stem cell self-renewal. Aldehyde dehydrogenase activity distinguished mesenchymal GSCs. The efficacy of Abx with TMZ was evaluated in GSC-expressing CK9751 PDC and mesenchymal patient-derived xenografts (PDXs). RESULTS: In PDCs (CK9495 and CK9751), Abx decreased the DNA repair machinery (RAD51, CHK1, Ku70, and MGMT) and induced apoptosis. Focused ATAC-seq analysis for promoters of DNA repair (RAD51, Ku70, CHK1, and BRCA1) and stemness (CD44, KLF4, c-Myc, and BMI1) revealed Abx decreased chromatin accessibility. Abx decreased stem cell self-renewal and reduced the mesenchymal stem cell signature (CD44, ALDH1A3 expression, and ALDH1 activity) in vitro GBM models. Abx reduced tumor growth and stemness markers in CK9751 PDC and mesenchymal PDXs. CONCLUSION: Abx reduced both DNA repair machinery and GSC markers by decreasing chromatin accessibility. Abx reduced tumor growth and mesenchymal GSCs in vitro and in vivo in GBM PDC and PDX models, supporting Abx's potential to prevent GSC-mediated therapy resistance and improve patient survival. Glioblastoma is a fast‑growing brain cancer that often comes back because current treatments fail to eliminate a small group of highly resistant cells called glioma stem cells. The study tested a drug called abexinostat, which blocks certain enzymes involved in gene regulation, to see whether it could target both regular tumor cells and these stem‑like cells. The researchers found that abexinostat reduced key DNA‑repair proteins—“abexinostat decreased the DNA repair machinery (RAD51, CHK1, Ku70, and MGMT)”—making cancer cells more vulnerable and triggering cell death. It also lowered markers of stemness, including CD44 and ALDH1A3, and reduced the ability of stem‑like cells to form new tumor spheres. Abexinostat effectively slowed tumor growth in both cell models and mouse models. Overall, the findings suggest that pairing abexinostat with current therapy could help prevent tumor recurrence by eliminating the hard‑to‑kill stem cell population.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Perumalsamy B, Vengoji R, Thiraviyam A, et al. Abexinostat attenuates temozolomide-resistant glioma stem cells. Neuro Oncol. 2026. PMID: 42616000. doi:10.1093/neuonc/noag193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。